ArticleMaedica2025
Clinical Significance of Micrometastases and Isolated Tumor Cells in Breast Cancer.
Article in Maedica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We decided to do a literature search for information about the clinical significance of micrometastases (pN1mi) and isolated tumor cells (ITCs). A detailed search was conducted in the existing bibliography. We found that pN1mi and ITCs had differences in prognosis and were handled in a different way. However, some researchers do not accept this difference. Many studies have shown no differences in their prognosis and the distinction of these terms is questioned. This fact is attributed to different definitions, diagnostic approaches that have been used and not well organised research. For their diagnosis, single hematoxylin and eosin (H) stain slide section, and not routine immunohistochemical (IHC) stain, is recommended, despite a lot of institutions perform multiple level sections and IHC stains for each block of sentinel lymph nodes (SLNs). Once the limits within pN1mi and ITCs were defined, they have been based in small data, and here is an area where we should focus and build evidence based definitions that have proven differences and importance in clinical management. As for their therapy, in ITCs cases, axillary lymph node dissection (ALND) is omitted, but a large amount of data questions the safety of this omission. In pN1mi cases, ALND is performed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.